These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Vascular endothelial growth factor in patients with exudative age-related macular degeneration treated with ranibizumab. Muether PS; Hermann MM; Viebahn U; Kirchhof B; Fauser S Ophthalmology; 2012 Oct; 119(10):2082-6. PubMed ID: 22920670 [TBL] [Abstract][Full Text] [Related]
4. The role of posterior vitreous detachment on the efficacy of anti-vascular endothelial growth factor intravitreal injection for treatment of neovascular age-related macular degeneration. Neudorfer M; Fuhrer AE; Zur D; Barak A Indian J Ophthalmol; 2018 Dec; 66(12):1802-1807. PubMed ID: 30451182 [TBL] [Abstract][Full Text] [Related]
5. Effect of posterior vitreous detachment on treat-and-extend versus monthly ranibizumab for neovascular age-related macular degeneration. Waldstein SM; Coulibaly L; Riedl S; Sadeghipour A; Gerendas BS; Schmidt-Erfurth UM Br J Ophthalmol; 2020 Jul; 104(7):899-903. PubMed ID: 31563866 [TBL] [Abstract][Full Text] [Related]
6. Influence of the Vitreoretinal Interface on the Treatment with Anti-VEGF for Exudative Age-Related Macular Degeneration. Gil P; Gil J; Oliveira N; Laíns I; Camilo ENR; Fonseca C; Raimundo M; Cachulo MDL; Silva R Ophthalmologica; 2018; 240(1):29-36. PubMed ID: 29734180 [TBL] [Abstract][Full Text] [Related]
7. Effects of posterior vitreous detachment on aqueous humour levels of VEGF and inflammatory cytokines. Takahashi H; Nomura Y; Tan X; Fujino Y; Kawashima H; Yanagi Y Br J Ophthalmol; 2015 Aug; 99(8):1065-9. PubMed ID: 25722492 [TBL] [Abstract][Full Text] [Related]
8. Aqueous vascular endothelial growth factor after intravitreal injection of pegaptanib or ranibizumab in patients with age-related macular degeneration. Sawada O; Miyake T; Kakinoki M; Sawada T; Kawamura H; Ohji M Retina; 2010; 30(7):1034-8. PubMed ID: 20616682 [TBL] [Abstract][Full Text] [Related]
9. Dynamics of Inflammatory Factors in Aqueous Humor during Ranibizumab or Aflibercept Treatment for Age-Related Macular Degeneration. Motohashi R; Noma H; Yasuda K; Kotake O; Goto H; Shimura M Ophthalmic Res; 2017; 58(4):209-216. PubMed ID: 28796997 [TBL] [Abstract][Full Text] [Related]
10. Aqueous vascular endothelial growth factor and ranibizumab concentrations after monthly and bimonthly intravitreal injections of ranibizumab for age-related macular degeneration. Wang X; Sawada T; Kakinoki M; Miyake T; Kawamura H; Saishin Y; Liu P; Ohji M Graefes Arch Clin Exp Ophthalmol; 2014 Jul; 252(7):1033-9. PubMed ID: 24196779 [TBL] [Abstract][Full Text] [Related]
11. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial. Zehetner C; Kralinger MT; Modi YS; Waltl I; Ulmer H; Kirchmair R; Bechrakis NE; Kieselbach GF Acta Ophthalmol; 2015 Mar; 93(2):e154-9. PubMed ID: 25488124 [TBL] [Abstract][Full Text] [Related]
12. Long-term stability of vascular endothelial growth factor suppression time under ranibizumab treatment in age-related macular degeneration. Muether PS; Hermann MM; Dröge K; Kirchhof B; Fauser S Am J Ophthalmol; 2013 Nov; 156(5):989-993.e2. PubMed ID: 23938122 [TBL] [Abstract][Full Text] [Related]
14. Effects of core vitrectomy in the treatment of age-related macular degeneration. Schramm K; Mueller M; Koch FH; Singh P; Kohnen T; Koss MJ Acta Ophthalmol; 2014 Aug; 92(5):465-72. PubMed ID: 24690440 [TBL] [Abstract][Full Text] [Related]
15. Aqueous humor levels of vascular endothelial growth factor before and after intravitreal bevacizumab in type 3 versus type 1 and 2 neovascularization. A prospective, case-control study. dell'Omo R; Cassetta M; dell'Omo E; di Salvatore A; Hughes JM; Aceto F; Porcellini A; Costagliola C Am J Ophthalmol; 2012 Jan; 153(1):155-61.e2. PubMed ID: 21861975 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of Aqueous Flare Levels Following Intravitreal Ranibizumab Injection for Neovascular Age-related Macular Degeneration. Uzun A; Yalcindag FN; Demirel S; Batýoðlu F; Ozmert E Ocul Immunol Inflamm; 2017 Apr; 25(2):229-232. PubMed ID: 26828124 [TBL] [Abstract][Full Text] [Related]
18. Profile of intraocular immune mediators in patients with age-related macular degeneration and the effect of intravitreal bevacizumab injection. Agawa T; Usui Y; Wakabayashi Y; Okunuki Y; Juan M; Umazume K; Kezuka T; Takeuchi M; Yamauchi Y; Goto H Retina; 2014 Sep; 34(9):1811-8. PubMed ID: 24801651 [TBL] [Abstract][Full Text] [Related]
19. THE INFLUENCE OF VITREOMACULAR ADHESION ON OUTCOMES AFTER AFLIBERCEPT THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. McKibbin MA; Suter CA; Willis TA Retina; 2015 Oct; 35(10):1951-6. PubMed ID: 25932561 [TBL] [Abstract][Full Text] [Related]
20. Role of posterior vitreous detachment on outcome of anti-vascular endothelial growth factor treatment in age-related macular degeneration. Üney GÖ; Ünlü N; Acar MA; Hazirolan D; Altiparmak UE; Yalniz-Akkaya Z; Örnek F Retina; 2014 Jan; 34(1):32-7. PubMed ID: 23751943 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]